1
|
Marks J, Yin J, Halmos B, Bazhenova L, Ramalingam S, Marmarelis M, Xiu J, Walker P, Oberley M, Ma P, Liu S. MA05.08 MET Exon 14 Skipping Mutation in Non-Small Cell Lung Cancer (NSCLC) by Specific Mutation, Histology, and Smoking History. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
2
|
Wang JY, Xiu J, Baca Y, Arai H, Battaglin F, Kawanishi N, Soni S, Zhang W, Millstein J, Shields AF, Grothey A, Weinberg BA, Marshall JL, Lou E, Khushman M, Sohal DPS, Hall MJ, Oberley M, Spetzler D, Shen L, Korn WM, Lenz HJ. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy. Ann Oncol 2021; 32:906-916. [PMID: 33798656 DOI: 10.1016/j.annonc.2021.03.203] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2020] [Revised: 03/21/2021] [Accepted: 03/28/2021] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The impact of molecular alterations on programmed death-ligand 1 (PD-L1) combined positive score (CPS) is not well studied in gastroesophageal adenocarcinomas (GEAs). We aimed to characterize genomic features of tumors with different CPSs in GEAs. PATIENTS AND METHODS Genomic alterations of 2518 GEAs were compared in three groups (PD-L1 CPS ≥ 10, high; CPS = 1-9, intermediate; CPS < 1, low) using next-generation sequencing. We assessed the impact of gene mutations on the efficacy of immune checkpoint inhibitors (ICIs) and tumor immune environment based on the Memorial Sloan Kettering Cancer Center and The Cancer Genome Atlas databases. RESULTS High, intermediate, and low CPSs were seen in 18%, 54% and 28% of GEAs, respectively. PD-L1 positivity was less prevalent in women and in tissues derived from metastatic sites. PD-L1 CPS was positively associated with mismatch repair deficiency/microsatellite instability-high, but independent of tumor mutation burden distribution. Tumors with mutations in KRAS, TP53, and RAS-mitogen-activated protein kinase (MAPK) pathway were associated with higher PD-L1 CPSs in the mismatch repair proficiency and microsatellite stability (pMMR&MSS) subgroup. Patients with RAS-MAPK pathway alterations had longer overall survival (OS) from ICIs compared to wildtype (WT) patients [27 versus 13 months, hazard ratio (HR) = 0.36, 95% confidence interval (CI): 0.19-0.7, P = 0.016] and a similar trend was observed in the MSS subgroup (P = 0.11). In contrast, patients with TP53 mutations had worse OS from ICIs compared to TP53-WT patients in the MSS subgroup (5 versus 21 months, HR = 2.39, 95% CI: 1.24-4.61, P = 0.016). CONCLUSIONS This is the largest study to investigate the distinct genomic landscapes of GEAs with different PD-L1 CPSs. Our data may provide novel insights for patient selection using mutations in TP53 and RAS-MAPK pathway and for the development of rational combination immunotherapies in GEAs.
Collapse
Affiliation(s)
- J Y Wang
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Xiu
- Caris Life Sciences, Phoenix, USA
| | - Y Baca
- Caris Life Sciences, Phoenix, USA
| | - H Arai
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - F Battaglin
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - N Kawanishi
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - S Soni
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - W Zhang
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Millstein
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - A F Shields
- Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, USA
| | - A Grothey
- GI Cancer Research, West Cancer Center and Research Institute, Germantown, USA
| | - B A Weinberg
- Division of Hematology and Oncology, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
| | - J L Marshall
- Division of Hematology and Oncology, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, USA
| | - E Lou
- Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, University of Minnesota, Minneapolis, USA
| | - M Khushman
- Department of Interdisciplinary Clinical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, USA
| | - D P S Sohal
- Division of Hematology/Oncology, University of Cincinnati, Cincinnati, USA
| | - M J Hall
- Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, USA
| | | | | | - L Shen
- Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China
| | - W M Korn
- Caris Life Sciences, Phoenix, USA
| | - H J Lenz
- Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, USA.
| |
Collapse
|
3
|
Roth L, O'Donohue T, Chen Z, Bartlett N, Martin-Doyle W, Barth M, Davies K, Christian B, Casulo C, Godfrey J, Oberley M, Alexander S, Weitzman S, Appel B, Svoboda J, Afify Z, Pauly M, Dave H, Gardner R, Stephens D, Zeitler W, Forlenza C, Levine J, Williams M, Bollard C, Leonard J. OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: a MULTICENTER RETROSPECTIVE ANALYSIS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_48] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- L.G. Roth
- Pediatrics; Weill Cornell Medical College; New York USA
| | - T. O'Donohue
- Pediatrics; Weill Cornell Medical College; New York USA
| | - Z. Chen
- Healthcare Policy and Research; Weill Cornell Medical College; New York New York USA
| | - N. Bartlett
- Department of Medicine; Washington University School of Medicine; St. Louis Missouri USA
| | - W. Martin-Doyle
- Department of Medicine; Brigham and Women's Hospital; Boston Massachusetts USA
| | - M.J. Barth
- Department of Pediatrics; Roswell Park Cancer Institute and University at Buffalo; Buffalo New York USA
| | - K. Davies
- Department of Pediatrics; Dana Farber Cancer Institute; Boston Massachusetts USA
| | - B. Christian
- Division of Hematology; The Ohio State University and Arthur G. James Cancer Hospital; Columbus Ohio USA
| | - C. Casulo
- Department of Medicine; University of Rochester Medical Center; Rochester New York USA
| | - J. Godfrey
- Department of Medicine; University of Chicago; Chicago Illinois USA
| | - M.J. Oberley
- Department of Pediatrics; Keck School of Medicine; Los Angeles California USA
| | - S. Alexander
- Division of Haematology/Oncology; Hospital for Sick Children; Toronto Ontario Canada
| | - S. Weitzman
- Division of Haematology/Oncology; Hospital for Sick Children; Toronto Ontario Canada
| | - B. Appel
- Department of Pediatrics; Hackensack University Medical Center; Hackensack New Jersey USA
| | - J. Svoboda
- Lymphoma Program, Abramson Cancer Center; University of Pennsylvania; Philadelphia Pennsylvania USA
| | - Z. Afify
- Department of Pediatrics; University of Utah; Salt Lake City Utah USA
| | - M. Pauly
- Department of Pediatrics; Emory University; Atlanta Georgia USA
| | - H. Dave
- Department of Pediatrics; The George Washington University and Children's National Health System; Washington District of Columbia USA
| | - R. Gardner
- Department of Pediatrics; Seattle Children's Hospital; Seattle WA USA
| | - D.M. Stephens
- Department of Medicine; University of Utah; Salt Lake City Utah USA
| | - W.A. Zeitler
- Department of Medicine; University of Iowa; Iowa City Iowa USA
| | - C. Forlenza
- Department of Pediatrics; Memorial Sloan Kettering Cancer Center; New York New York USA
| | - J. Levine
- Department of Pediatrics; Columbia University; New York New York USA
| | - M.E. Williams
- Hematology/Oncology Division and Cancer Center; University of Virginia School of Medicine; Charlottesville Virginia USA
| | - C.M. Bollard
- Department of Pediatrics; The George Washington University and Children's National Health System; Washington District of Columbia USA
| | - J.P. Leonard
- Department of Medicine; Weill Cornell Medical College; New York New York USA
| |
Collapse
|